Jeil-Kirin renames itself Kyowa Hakko Kirin Korea

Published: 2012-05-31 06:56:00

Updated: 2012-05-31 06:56:00

Jeil-Kirin Pharma plans to change its English corporate name to Kyowa Hakko Kirin Korea from June 1 in a bid to make tremendous strides across key scientific fields, including oncology, immunology and nephrology.

Jeil-Kirin’s leading products include A2 Grasin (filgrastim), Nesp (darbepoetin-α...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK